Analyst Price Targets — NVCR
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 12, 2026 11:04 am | — | H.C. Wainwright | $47.00 | $13.74 | TheFly | Novocure price target raised to $47 from $39 at H.C. Wainwright |
| January 13, 2026 11:03 am | — | H.C. Wainwright | $39.00 | $14.18 | TheFly | Novocure price target lowered to $39 from $42 at H.C. Wainwright |
| January 5, 2026 2:54 pm | — | Evercore ISI | $20.00 | $13.71 | TheFly | Novocure price target lowered to $20 from $22 at Evercore ISI |
| October 30, 2025 4:11 pm | — | H.C. Wainwright | $42.00 | $13.18 | TheFly | Novocure price target raised to $42 from $38 at H.C. Wainwright |
| July 24, 2025 8:09 pm | Larry Biegelsen | Wells Fargo | $14.50 | $12.54 | TheFly | Novocure downgraded to Equal Weight from Overweight at Wells Fargo |
| December 2, 2024 11:00 am | Vijay Kumar | Evercore ISI | $30.00 | $26.43 | StreetInsider | Evercore ISI Upgrades NovoCure Ltd. (NVCR) to Outperform 'into Panova readout on asymmetric risk/reward' |
| October 16, 2024 6:06 am | Emily Bodnar | H.C. Wainwright | $30.00 | $17.78 | StreetInsider | H.C. Wainwright Upgrades NovoCure Ltd. (NVCR) to Buy |
| July 26, 2024 6:48 am | Emily Bodnar | H.C. Wainwright | $24.00 | $18.26 | StreetInsider | NovoCure Ltd. (NVCR) PT Raised to $24 at H.C. Wainwright |
| May 3, 2024 6:46 am | Emily Bodnar | H.C. Wainwright | $22.00 | $14.19 | StreetInsider | NovoCure Ltd. (NVCR) PT Lowered to $22 at H.C. Wainwright |
| May 2, 2024 4:48 pm | Vijay Kumar | Evercore ISI | $14.50 | $14.78 | StreetInsider | NovoCure Ltd. (NVCR) PT Lowered to $14.50 at Evercore ISI |
Latest News for NVCR
NovoCure (NASDAQ: NVCR - Get Free Report) and Alterity Therapeutics (NASDAQ: ATHE - Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, dividends, risk, profitability, valuation and earnings. Risk and Volatility NovoCure has a beta of
JPMorgan Chase and Co. lifted its stake in NovoCure Limited (NASDAQ: NVCR) by 104.2% in the undefined quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 282,184 shares of the medical equipment provider's stock after buying an additional 144,024 shares during the period. JPMorgan
BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) will report financial results for the first quarter 2026 on April 30, 2026, before the U.S. financial markets open. Novocure management will host a conference call and webcast at 8:00 a.m. EDT, April 30, to discuss the company's financial results for the three-month period that ended March 31, 2026. To access the conference call by phone, use the following…
The stock is gaining traction as the company reported a disease control rate of 74.4%, significantly higher than the historical control of 48%.
BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) announced positive results today from the Phase 2 PANOVA-4 trial of Tumor Treating Fields (TTFields) therapy concomitant with atezolizumab (Tecentriq®), gemcitabine and nab-paclitaxel (gem/nab-pac) as a first-line treatment for metastatic pancreatic ductal adenocarcinoma (mPDAC). PANOVA-4 met its pre-specified primary endpoint, achieving a statistically…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for NVCR.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.